fulvestrant

CAPItello-291: Capivasertib in Breast Cancer

The CAPItello-291 Trial: A New Horizon in Breast Cancer Treatment The CAPItello-291 Trial, a Phase III double-blind randomized trial conducted in 2023, has significantly contributed to the evolving landscape of breast cancer treatment, particularly for hormone receptor-positive advanced cases. Objective … Read More